DEALTALK-AstraZeneca not only game in town for deal-hungry Pfizer

Fri Nov 14, 2014 7:17am EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

(For more Reuters DEALTALKS, double click on )

* Pfizer reviewing takeover scenarios beyond Astra -sources

* Chance of U.S. firm renewing Astra pursuit seen receding

* Enforced cooling-off period ends on Nov. 26

* Pfizer taking close look at Actavis as target -sources

By Pamela Barbaglia and Sophie Sassard

LONDON, Nov 14 (Reuters) - Pfizer appears unlikely to make a fresh bid for AstraZeneca in 12 days time, when an enforced cooling-off period ends, and the U.S. drugmaker is now weighing other less risky targets.

People with direct knowledge of the situation said Pfizer has been reviewing different takeover scenarios with a U.S. investment bank ahead of Nov. 26, when it is allowed to renew its pursuit of AstraZeneca under UK takeover rules.

This includes a close analysis of the benefits of a tax-saving deal to buy Dublin-based generic drugmaker Actavis , which has a market value of around $64 billion against AstraZeneca's $94 billion.   Continued...